Supplementary Figures 1 - 7 from Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer

PDF file - 318K, Figure S1. DNA binding affinity of full-length PARP-1 and various domain combinations. Figure S2. DNA binding affinities of deltaZn2 PARP-1 variants. Figure S3. Cell viability dose response curves of MIA PaCa-2 cells treated with non-platinum based agents. Figure S4. DNA binding affinities for mutants of 1-366deltaZn2. Figure S5. Confirmation of genomic incorporation of the plasmids. Figure S6. Western blot analysis for PARP-1 in the AR reporter assay. Figure S7. Validation of protein concentration by SDS-PAGE gel analysis.